Patents by Inventor Glenn Ishioka

Glenn Ishioka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HLA-DR binding peptides and their uses
    Patent number: 10556943
    Abstract: The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 11, 2020
    Assignees: Mayo Foundation for Medical Education and Research, University of Washington
    Inventors: Keith L. Knutson, Mary L. Disis, John D. Fikes, Melanie Beebe, Glenn Ishioka
  • HLA-A2 tumor associated antigen peptides and compositions
    Patent number: 9913884
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 13, 2018
    Assignee: OSE Pharma International SA
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-DR BINDING PEPTIDES AND THEIR USES
    Publication number: 20170342126
    Abstract: The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
    Type: Application
    Filed: December 16, 2016
    Publication date: November 30, 2017
    Inventors: Keith L. Knutson, Mary L. Disis, John D. Fikes, Melanie Beebe, Glenn Ishioka
  • HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS
    Publication number: 20170028041
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 2, 2017
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-DR BINDING PEPTIDES AND THEIR USES
    Publication number: 20140377340
    Abstract: The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Keith L. Knutson, Mary L. Disis, John D. Fikes, Melanie Beebe, Glenn Ishioka
  • Heteroclitic analogs and related methods
    Patent number: 8741576
    Abstract: Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: June 3, 2014
    Assignee: Epimunne Inc.
    Inventors: Shabnam Tangri, Alessandro Sette, Glenn Ishioka, John D. Fikes
  • HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS
    Publication number: 20120183598
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: August 18, 2011
    Publication date: July 19, 2012
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-A2 tumor associated antigen peptides and compositions
    Patent number: 8007810
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: August 30, 2011
    Assignee: Biotech Synergy, Inc.
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • HLA-DR BINDING PEPTIDES AND THEIR USES
    Publication number: 20100310640
    Abstract: The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
    Type: Application
    Filed: October 30, 2008
    Publication date: December 9, 2010
    Inventors: Keith L. Knutson, Mary L. Disis, John D. Fikes, Melanie Beebe, Glenn Ishioka
  • HLA-A2 Tumor Associated Antigen Peptides and Compositions
    Publication number: 20100209493
    Abstract: A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 19, 2010
    Applicant: IDM Pharma, Inc.
    Inventors: John D. FIKES, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • Heteroclitic analogs and related methods
    Publication number: 20090169574
    Abstract: Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 2, 2009
    Inventors: Shabnam Tangri, Alessandro Sette, Glenn Ishioka, John D. Fikes
  • Hla-A2 Tumor Associated Antigen Peptides and Compositions
    Publication number: 20080274129
    Abstract: A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
    Type: Application
    Filed: April 16, 2004
    Publication date: November 6, 2008
    Inventors: John D. Fikes, Glenn Ishioka, Alessandro Sette, Robert W. Chesnut
  • Heteroclitic analogs and related methods
    Publication number: 20060018915
    Abstract: Heteroclitic analogs of class I epitopes are prepared by providing conservative, semi-conservative, or non-conservative amino acid substitutions at positions 3 and/or 4 and/or 5 and/or 6 and/or 7 and/or 8 and/or 9 and/or 10 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wild-type epitopes.
    Type: Application
    Filed: April 7, 2003
    Publication date: January 26, 2006
    Inventors: Glenn Ishioka, John Fikes, Shabnam Tangri, Alessandro Sette
  • Heteroclitic analogs and related methods
    Publication number: 20030143672
    Abstract: Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes.
    Type: Application
    Filed: April 5, 2002
    Publication date: July 31, 2003
    Applicant: Epimmune, Inc.
    Inventors: Shabnam Tangri, Alessandro Sette, Glenn Ishioka, John D. Fikes